Junwei Shi

Associate Professor at UPenn

[Junwei Shi @junwei_s]

One more thing. Another work led by the dedicated and talented scientists @DiqiuR and Shangshang Wang, stemming from our long-standing collaboration with Rahul Kohli and @andyjminn’s labs at Penn.
https://t.co/3YrjJQ5nwE

[E. John Wherry @EJohnWherry]

Very excited to get this new work by Shin Ngiow up on #bioRxiv. We may be blocking PD-1 too long causing detrimental effects on Tpex cells. A drug holiday approach may be beneficial. Also some cool new Tpex biology here. #immunopharmacology https://t.co/TjkOE423Gu

[Junwei Shi @junwei_s]

@KentsisResearch haha, would love to. also great to catch up with my MSKCC friends and collaborators

[Nature Biotechnology @NatureBiotech]

Inducible, split base editors for in vivo cancer functional genomics https://t.co/KHr0O6NuT2

[Junwei Shi @junwei_s]

@KSusztak @zhtianp2 @KaiTanLab1 @TomZhendong Thank you, Katalin

[Junwei Shi @junwei_s]

Have been missing twitter. Excited to share our new study. This was a close collaboration with Kathrin Bernt's and @KaiTanLab1 labs, led by the talented and unstoppable @TomZhendong and Sixiang Yu
https://t.co/iq30DVhpiK

[Junwei Shi @junwei_s]

@hao_wu_7 @KaiTanLab1 @TomZhendong thank you, Hao!

[Junwei Shi @junwei_s]

Our improved, inducible base editing system (seBE) provides controllable and robust genome editing to systematically identify functionally relevant key residues for cancer functional genomics.

[Junwei Shi @junwei_s]

One more thing. Another work led by the dedicated and talented scientists @DiqiuR and Shangshang Wang, stemming from our long-standing collaboration with Rahul Kohli and @andyjminn’s labs at Penn.
https://t.co/3YrjJQ5nwE

[Junwei Shi @junwei_s]

A high-resolution tiling base editing mutagenesis screen targeting Adar1, an adenosine deaminase associated with tumor immunity, identified both loss-of-function and gain-of-function alleles.

[Junwei Shi @junwei_s]

This robust and general CRISPR-based functional genomics approach in primary AML patient samples opens up new opportunities to prioritize/identify therapeutic targets and understand resistance mechanisms in AML.

[Junwei Shi @junwei_s]

CRISPR knockout screens reveal both shared and distinct AML dependencies in primary samples. CRISPRi screens identify essential cis-regulatory elements in PDXs. We further used Perturb-seq to dissect regulatory networks and cellular heterogeneity in primary AML cells.

[Penn Medicine CSO @PennMedCSO]

ft. @TomZhendong, S. Yu, Y. Liu, L. Liu, @junwei_s (@Penn_CBIO/ @PennEpiInst), @jackiejpeng (@UPennGCB), D. Barrett, J. Sussman, C. Chen, A. Thadi, F. Alikarami, J. Xu, @cdktmw, @kathrinbernt (@CHOP_Research) & Martin Carroll (@PennCancer) @CAMBUpenn https://t.co/v9N0efCRLT

[Institute for Immunology and Immune Health (I3H) @UPenn_I3H]

Healthy blood cells can live without ARHGAP45—but acute myeloid leukemia cells can’t. 🩸 Junwei Shi, PhD, Associate Professor of Cancer Biology (@junwei_s) and team show a CAR T + CDC42 inhibition strategy could target AML with minimal side effects. https://t.co/2mD0DW5rQs

[Penn Medicine CSO @PennMedCSO]

Systematic evaluation of GAPs and GEFs identifies a targetable dependency for hematopoietic malignancies ft. Yuqiao Liu & @junwei_s (@Penn_CBIO) @CD_AACR https://t.co/gnC1Am9Lh4

[Junwei Shi @junwei_s]

@AbdelWahablab @DaniyanMd @PuZhang09980432 @TomZhendong likewise

[Junwei Shi @junwei_s]

Excited to share our new study, in close collaboration with @AbdelWahablab and @DaniyanMd led by the exceptionally talented scientists @PuZhang09980432 and @TomZhendong
https://t.co/JLSNt1putl

[Junwei Shi @junwei_s]

@AbdelWahablab @DaniyanMd @PuZhang09980432 @TomZhendong This has truly been a fantastic collaboration that I can only dream of @AbdelWahablab, @DaniyanMd, @TomZhendong, and @PuZhang09980432

[Junwei Shi @junwei_s]

@AbdelWahablab @DaniyanMd @PuZhang09980432 @TomZhendong Even more exciting: CDC42 inhibition not only synergizes with ARHGAP45 loss intrinsically in leukemia cells, but also enhances TCR-CAR T cell function. A dual strategy to target cancer cells and augment immune responses.